Oxybutynin transdermal therapeutic system combination
AssigneeChase Pharmaceuticals Corporation
InventorsThomas N. CHASE, Kathleen E. CLARENCE-SMITH
Life of this patent
Estimating the term…
Abstract
There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. In this combination, the acetylcholinesterase inhibitor (AChEI) is present at a dose that is higher than the maximal recommended dose, per unit form. In particular, the transdermal therapeutic system comprising oxybutynin is in combination with rivastigmine in a transdermal formulation or oral form.
Claims22
A pharmaceutical combination comprising, as Components:
- (a) oxybutynin or a pharmaceutically acceptable salt thereof, in a transdermal therapeutic system (TTS);
- and
- (b) an acetylcholinesterase inhibitor (AChEI).
A method for treating a hypocholinergic disorder of the central nervous system, which comprises administering to a patient in need of said treatment a combination comprising, as Components:
- (a) oxybutynin or a pharmaceutically acceptable salt thereof, in a transdermal therapeutic system (TTS);
- and
- (b) an acetylcholinesterase inhibitor (AChEI).
Dependencies are inferred from the claim text.